Lipodystrophy severity does not contribute to HAART nonadherence

AIDS and Behavior

Volumn 10, Issue 3, 2006, Pages 273-277

  Collins, Evan J ^a,b   Burgoyne, Robert W ^a,b   Wagner, Cheryl A ^c   Abbey, Susan E ^a,b   Halman, Mark H ^b,d   Nur, Margaret L ^a   Walmsley, Sharon L ^a,e  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adherence; Antiretroviral therapy; HIV AIDS; Lipodystrophy; Symptoms

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BEHAVIORAL SCIENCE; BODY FAT DISTRIBUTION; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; SAMPLE;

AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SOCIAL SUPPORT; TREATMENT REFUSAL;

EID: 33745234764     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-005-9048-4     Document Type: Article

References (21)

1. Ammassari, A., Antinori, A., Cozzi-Lepri, A., Trotta, M. P., Nasti, G., Ridolfo, A. L., Mazzotta, F., Wu, A. W., D'Arminio Monforte, A., and Galli, M. (2002a). Relationship between HAART adherence and adipose tissue alterations. Journal of Acquired Immune Deficiency Syndromes, 31, S140-S144.
2. Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., Lo Caputo, S., Narciso, P., Pauluzzi, S., Carosi, G., Nappa, S., Piano, P., Izzo, C. M., Lichtner, M., Rezza, G., Monforte, A., Ippolito, G., D'Arminio Moroni, M., Wu, A. W., and Antinori, A. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445-449.
3. Ammassari, A., Trotta, M. P., Murri, R., Castelli, F., Narciso, P., Noto, P., Vecchiet, J., D'Arminio Monforte, A., Wu, A. W., and Antinori, A. (2002b). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31, S123-S127.
4. Bartlett, J. A. (2002). Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes, 29, S2-S10.
5. Bassetti, S., Battegay, M., Furrer, H., Rickenback, M., Flepp, M., Kaiser, L., Telenti, A., Vernazza, P. L., Bernasconi, E., and Sudre, P. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Journal of Acquired Immune Deficiency Syndromes, 21, 114-119.
6. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D., and Cooper, D. A. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51-F58.
7. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G., Chisholm, D., and Cooper, D. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study. Lancet, 353, 2093-2099.
8. Collins, E. J., Wagner, C. A., and Walmsley, S. L. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader, 10, 546-550.
9. DeMasi, R. A., Graham, N. M., Tolson, J. M., Pham, S. V., Capuano, G. A., Fisher, R. L., Shaefer, M. S., Pakes, G. E., Sawyerr, G. A., and Eron, J. J. (2001). Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome. Advances in Therapy, 18, 163-173.
10. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., Salmon, D., Moatti, J. P., and Leport, C. (2001a). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15, 2441-2444.
11. Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., Cailleton, V., Leport, C. and Moatti, J. P. (2001b). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38-45.
12. Ferguson, T. F., Stewart, K. E., Funkhouser, E., Tolson, J., Westfall, A. O., and Saag, M. S. (2002). Patient-perceived barriers to antiretroviral adherence: Associations with race. AIDS Care, 14, 607-617.
13. Fong, O. W., Ho, C. F., Fung, L. Y., Lee, F. K., Tse, W. H., Yuen, C. Y., Sin, K. P., and Wong, K. H. (2003). Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Medicine, 4, 133-138.
14. Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., and Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23, 386-395.
15. Guaraldi, G., Murri, R., Orlando, G., Orlandi, E., Sterrantino, G., Borderi, M., Grosso, C., Cattelan, M. A., Nardini, G., Beghetto, B., Antinori, A., Esposito, R., and Wu, A. W. (2003). Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clinical Trials, 4, 99-106.
16. Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaugnessy, M. V., and Montaner, J. S. (2001). Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS, 15, 231-239.
17. Jhingran, P., Tolson, J., Scott-Lennox, J., Jordan, J., and Pham, S. (1997). Development and content validation of an HIV-specific Patient Medication Adherence Questionnaire (PMAQ). Paper presented at the 37th Interscience Conference on Anti-Microbrial Agents Chemotherapy, Toronto, Canada.
18. Justice, A. C., Rabeneck, L., Hays, R. D., Wu, A. W., and Bozzette, S. A. (1999). Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: A comparison with self-reported symptoms. Journal of Acquired Immune Deficiency Syndromes, 21, 126-133.
19. McCarron, B., Pithie, C., and Mathers, L. (1998). Adherence to anti-retroviral therapy in Glasgow HIV patients. AIDS, 12(Suppl 4), S62. Abstract P181.
20. Paton, N. I., Earnest, A., Ng, Y. M., Karim, F., and Aboulhab, J. (2002). Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: Prevalence, associated factors and psychological impact. Clinical Infectious Diseases, 35, 1244-1249.
21. Shafer, R. W., and Vuitton, D. A. (1999). Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomedicine and Pharmacotherapy, 53, 73-86.